According to TipRanks.com, Ruiz has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -28.0% and a 15.0% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, Xeris Pharmaceuticals, and Atea Pharmaceuticals.
Currently, the analyst consensus on ContraFect is a Strong Buy with an average price target of $7.75.
Based on ContraFect’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $5.29 million. In comparison, last year the company had a net profit of $3.44 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ContraFect Corp. is a clinical stage biotechnology company , which engages in discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases. Its pipeline consists of CF-301, a bacteriophage-derived lysin with potent activity against Staphylococcus aureus bloodstream infections; and CF-404, which composed of three fully human monoclonal antibodies designed to treat all seasonal strains of human influenza. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.
Read More on CFRX:
- Robert W. Baird Sticks to Their Buy Rating for Axon Enterprise (AXON)
- Vericel (VCEL) Receives a Buy from Leerink Partners
- Kura Oncology (KURA) Gets a Buy Rating from Leerink Partners
- Leerink Partners Thinks CryoPort’s Stock is Going to Recover
- SAGE Therapeutics (SAGE) Receives a Hold from Leerink Partners